Tacrolimus topical - MC2 Therapeutics
Alternative Names: MC2 11; MC2-11 PAD™ Cream; PADeczemaLatest Information Update: 21 Apr 2023
At a glance
- Originator MC2 Biotek
- Developer MC2 Therapeutics
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Atopic dermatitis
Most Recent Events
- 21 Apr 2023 Preclinical trials in Atopic dermatitis in Germany (Topical) (MC2 Therapeutics pipeline, April 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Atopic-dermatitis in Germany (Topical, Cream)
- 14 Feb 2017 Chemical structure information added